ALT Q4 2024 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000-86.5% YoY

Gross Profit

$5,000100.0% margin

Operating Income

-$25M-497320.0% margin

Net Income

-$23M-463600.0% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$139M

Total Liabilities

$16M

Stockholders' Equity

$124M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$37,000	-86.5%
Gross Profit	$5,000	$37,000	-86.5%
Operating Income	-$25M	-$34M	+26.0%
Net Income	-$23M	-$32M	+26.7%